{"prompt": "['PREDM', 'Page 47', 'the differences. For each outcome measure (FPG, HbA1c, HOMA-IR, IGFBP-1), we will', 'obtain the difference Di for i=1,2, 41 and then we will assess if the mean differences', 'are significantly different from 0 using a one-sample t-test. We will also conduct analyses', 'to determine whether the effect of the combined intervention is noticeable at week 12. In', 'a similar manner, as discussed above, we will take the differences between week 12 and', 'baseline observations.', 'In addition, since we will have observations at three time points, we will also use a', 'Generalized Estimating Equations (GEE) approach to assess the pattern of change over', 'time using PROC GENMOD in SAS 9.4 and using compound symmetry as the working', 'covariance structure to account for correlation among repeated observations.', 'The exploratory outcomes of weight, body fat %, cholesterol and triglyceride measures,', 'systolic blood pressure (SBP), diastolic blood pressure (DBP), physical activity', '(NHANES-PAQ score, measured activity by accelerometer data and walking speed)', 'and HRQOL will also be assessed at baseline, week 12 and week 24 and, in the case of', 'frailty measures (walking speed, hand grip strength, lean muscle mass, exhaustion and', 'low activity) at baseline and week 24. Similar to the secondary outcomes above, the', 'mean difference from baseline to week 24 (and then week 12) in the outcome measures', 'will be assessed using a one sample t-test to determine if the mean difference for each', 'outcome is significantly different from 0.', '12.1 Anticipated Completion Dates', 'Anticipated Primary Completion Date: December 2022', 'Anticipated Study Completion Date December 2022', 'Initial version, dated: 04-10-20', 'IRB approkB', \"St. Jude date Children's Research Hospital\", 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']['PREDM', 'Page 48', '12.2 Summary of Primary and Secondary Objectives', 'Objective', 'Objective', 'Analysis', 'Resp', 'Stat', 'Safety', 'Analysis Measure', 'Analysis Title', 'Data', '# of', '#', 'Type', '#', 'Party', 'Collection', 'Participants', 'Time Frame', '1.0', 'P', '1', 'SBD', 'DK,', 'N', 'Combined metformin and lifestyle', 'Assess adherence to combined', 'Weeks 2, 4, 8,', '41', 'SMS', 'adherence, proportion of metformin', 'metformin and lifestyle change', '12, 16, 20,', 'pills taken and proportion of lifestyle', 'intervention', 'and 24', 'curriculum completed', '1.0', 'P', '2', 'SBD', 'DK,', 'Y', 'Safety of combined intervention,', 'Assess safety of combined', '41', 'SMS', 'CTCAE graded adverse events', 'intervention', '2.0', 'S', '1', 'SBD', 'DK,', 'N', 'Glycemic control (FPG, HbA1c),', 'Effect of intervention on', 'Baseline,', '41', 'SMS', 'change in FPG, HbA1c from', 'glycemic control', 'weeks 12, 24', 'baseline', '2.0', 'S', '2', 'SBD', 'DK,', 'N', 'Insulin resistance (HOMA-IR, IGF-', 'Effect of intervention on insulin', 'Baseline,', '41', 'SMS', 'BP1), change in HOMA-IR, IGF-', 'resistance', 'weeks 12, 24', 'BP1 from baseline', '3.0', 'S', '1', 'SBD,', 'DK,', 'N', 'Anthropometrics, change in weight,', 'Effect of intervention on weight', 'Baseline,', '41', 'KN', 'SMS', 'BMI, body fat % and waist-to-hip', 'and other anthropometric', 'weeks 12, 24', 'ratio from baseline', 'measures', '3.0', 'S', '2', 'SBD,', 'DK,', 'N', 'Physical activity, change in self-', 'Effect of intervention on', 'Baseline,', '41', 'KN', 'SMS', 'reported and accelerometer measures', 'physical activity', 'weeks 12, 24', 'of physical activity from baseline', '3.0', 'S', '3', 'SBD', 'DK,', 'N', 'Blood pressure, change in SBP and', 'Effect of intervention on blood', 'Baseline,', '41', 'SMS', 'DBP from baseline', 'pressure', 'weeks 12, 24', '3.0', 'S', '4', 'SBD', 'DK,', 'N', 'Lipid profile, change in lipid profile', 'Effect of intervention on lipid', 'Baseline,', '41', 'SMS', 'from baseline', 'profile', 'weeks 12, 24', '3.0', 'S', '5', 'SBD,', 'DK,', 'N', 'Frailty, change in frailty measures', 'Effect of intervention on', 'Baseline,', '41', 'KN', 'SMS', 'from baseline', 'measures of frailty', 'week 24', '3.0', 'S', '6', 'SBD', 'DK,', 'N', 'Health-related quality of life, change', 'Effect of intervention on', 'Baseline,', '41', 'SMS', 'in HRQOL by survey from baseline', 'HRQOL', 'weeks 12, 24', '3.0', 'S', '7', 'SBD', 'DK,', 'N', 'Future diabetes (GPG, HbA1c),', 'Effect of intervention on', 'All return', '41', 'SMS', 'proportion of participants who', 'diabetes long-term', 'SJLIFE core', 'develop diabetes', 'visits through', '6 years', '3.0', 'S', '8', 'SBD,', 'DK,', 'N', 'Participation in lifestyle program and', 'Assess lifestyle program', 'Baseline,', '41', 'TB', 'SMS', 'barriers to participation and', 'participation (logging, days', 'week 24', 'metformin adherence', 'accessed, etc) and relationship', 'to efficacy, assess barriers to', 'adherence and participation', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approval date: 00-00-00', 'IRB NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']\n\n###\n\n", "completion": "END"}